top of page

Visiting Adaptimmune on its investor day and ahead of this year's FDA decision for the TCR cell therapy afami-cel in synovial sarcoma

  • Apr 18, 2024
  • 1 min read

CEO Adrian Rawcliffe describes how Adaptimmune is preparing to launch what could be the first approved TCR based cell therapy in the United States and what the potential launch means for the company.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page